Safety of Selegiline (Deprenyl) in the Treatment of Parkinson's Disease

ISSN： 0114-5916

Source： Drug Safety, Vol.19, Iss.1, 1998-07, pp. : 11-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease

By Tábi Tamás Szökő Éva Vécsei László Magyar Kálmán

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 5, 2013-05 ,pp. : 629-636

Informa Healthcare

Access to resources Recommend Favorite

Orally disintegrating selegiline for the treatment of Parkinson's disease

By Löhle Matthias Storch Alexander

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 16, 2008-11 ,pp. : 2881-2891

Informa Healthcare

Access to resources Recommend Favorite

Safety of rasagiline for the treatment of Parkinson's disease

By Perez-Lloret Santiago Rascol Olivier

Expert Opinion on Drug Safety, Vol. 10, Iss. 4, 2011-07 ,pp. : 633-643

Informa Healthcare

Access to resources Recommend Favorite

Metabolism of Selegiline [(-)-Deprenyl)]

Current Medicinal Chemistry, Vol. 21, Iss. 13, 2014-04 ,pp. : 1522-1530

Bentham Science Publishers

Access to resources Recommend Favorite

The safety of dopamine agonists in the treatment of Parkinson's disease

By Bonuccelli Ubaldo Ceravolo Roberto

Expert Opinion on Drug Safety, Vol. 7, Iss. 2, 2008-03 ,pp. : 111-127

Informa Healthcare

Access to resources Recommend Favorite